10.50SEK+7.58%Mkt Cap: 228.72M SEKP/E: —Last update: 2026-05-13
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)555.00
PEG—
P/B0.41
P/S1.50
EV/EBITDA-8.76
EV/Revenue1.13
EPS (TTM)-4.68
EPS (Forward)0.02
Cash Flow & Leverage
FCF Yield-151.72%
FCF Margin-227.77%
Operating CF-250.69M SEK
CapEx (TTM)139.64M SEK
Net Debt/EBITDA1.44
Net Debt-28.28M SEK
Technical
SMA 507.985 (+31.5%)
SMA 20015.65 (-32.9%)
Beta0.89
S&P 52W Chg24.23%
Avg Vol (30d)75.81K
Avg Vol (10d)68.47K
Technical Indicators
RSI (14)60.1
MACD0.5691
MACD Signal0.6442
MACD Hist.-0.0751
BB Upper11.46 SEK
BB Middle9.895 SEK
BB Lower8.333 SEK
BB Width31.57%
ATR (14)1.090 SEK
Vol Ratio (20d)0.41x
52W Range
5.42116% of range38.10
52W High38.10 SEK
52W Low5.421 SEK
Profitability
Gross Margin58.76%
EBITDA Margin-12.89%
Profit Margin83.49%
Oper. Margin-237.46%
ROE22.70%
ROA18.95%
Revenue Growth-86.20%
Earnings Growth—
Balance Sheet
Debt/Equity0.10
Current Ratio7.12
Quick Ratio2.43
Book Value/Sh27.21 SEK
Cash/Share4.202 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateOct 17, 2025
Ownership
Shares Out.20.61M
Float15.03M
Insiders41.04%
Institutions6.26%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)15.00 SEK
Target Range15.00 SEK – 15.00 SEK
# Analysts1
Company
Market Cap228.72M SEK
Enterprise Value172.00M SEK
Revenue (TTM)152.35M SEK
Gross Profit89.55M SEK
Net Income (TTM)127.24M SEK
Revenue/Share9.273 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees29
Last Price10.50 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0007789409